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Achieving asthma control remains an elusive goal for the majority of patients worldwide.
Ensuring a correct diagnosis of asthma is the first step in assessing poor symptom control; this
requires returning to the basics of history taking and physical examination, in conjunction with
lung function measurement when appropriate. A number of factors may contribute to sub-
optimal asthma control. Concomitant rhinitis, a common co-pathology and contributor to poor
control, can often be identified by asking a simple question. Smoking too has been identified as
a cause of poor asthma control. Practical barriers such as poor inhaler technique must be ad-
dressed. An appreciation of patients’ views and concerns about maintenance asthma therapy
can help guide discussion to address perceptual barriers to taking maintenance therapy
(doubts about personal necessity and concerns about potential adverse effects). Further study
into, and a greater consideration of, factors and patient characteristics that could predict55 261666; fax: þ44 1224 550683.
ac.uk (J. Haughney).
8 Elsevier Ltd. All rights reserved.
1682 J. Haughney et al.individual responses to asthma therapies are needed. Finally, more clinical trials that enrol
patient populations reflecting the real world diversity of patients seen in clinical practice,
including wide age ranges, presence of comorbidities, current smoking, and differing ethnic
origins, will contribute to better individual patient management.
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Achieving asthma control remains an elusive goal for the
majority of patients worldwide.1e3 This troublesome reality
persists despite the availability for over two decades of
international asthma management guidelines and asthma
therapies of proven efficacy, at least for the highly selected
patient populations studied in controlled trial settings.4,5
Poor asthma control places a heavy burden on patients and
their families, as it manifests in increased rates of hospi-
talisations and emergency room and other urgent care
visits, in addition to activity limitations, night-time awak-
enings, and lost time from work and school.6 Moreover,
poor asthma control is expensive, accounting for most of
asthma-related health-care costs.7
An international initiative was begun in 2006, under the
auspices of the International Primary Care RespiratoryGroup (IPCRG), to examine the reasons for poor asthma
control and arrive at a consensus on how best to improve
the delivery of asthma care in the primary care setting,
where most patients with asthma are managed. The first
discussion centred around understanding the patient’s
perspective as a means of improving asthma control.8 A key
priority emerging from this discussion was the need to
identify and develop validated instruments (tools) to assess
asthma control and understand the reasons for poor control
for individual patients. Primary care providers work under
tight time constraints and often with limited diagnostic
facilities. Therefore, tools for use in primary care must be
simple and practical.
Building on the first discussion, a secondmeetingwas held
in September 2007 to examine common reasons for poor
asthma control and how these might be identified and
addressed in clinical practice. Here we report the discussion
of these important issues, including what sort of tools could
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Figure 1 Misuse of pressurised metered dose inhalers is
directly linked to decreased asthma stability: frequency
distribution of the number of errors or omissions in inhalation
technique (left axis; striped bars) and relationship between
this number and the Asthma Instability Score (AIS; mean SEM,
right axis; grey bars). Correlation between the number of
errors and AIS (linear regression analysis): rZ 0.3, p< 0.0001.
Reprinted with permission from Giraud et al.13
Understanding poor asthma control 1683be used to identify and correct specific causes of poor
control, namely, the wrong diagnosis, poor inhaler tech-
nique, smoking, co-morbid rhinitis, individual variation in
response to treatment, and poor adherence to treatment.
Reasons for poor asthma control: the wrong
diagnosis
Patients may be given a diagnosis of asthma on the basis of
a compatible history and a successful trial of therapy. If
asthma symptoms do not respond as expected to treatment,
an important stepdbefore increasing doses or adding med-
icationsdshould be to review and attempt to confirm the
diagnosis of asthma. Other conditions share common
features with asthma, and other confounding illness, such as
allergic rhinitis, can worsen asthma symptoms.
Asthma diagnosis: the basics
Returning to the basics of making a diagnosis is essential.
This includes a thorough history, physical examination, and
appropriate diagnostic testing. Ideally, a diagnosis of
asthma should be based on objective evidence of reversible
airflow obstruction. Because asthma is a variable disease,
challenge testing may be required. Normal spirometry
results do not exclude the diagnosis. Spirometry, it seems,
is not always performed, even when the equipment is
available.1 Moreover, many primary care clinicians world-
wide may not have the equipment or sufficient time or
experience to measure peak expiratory flow (PEF) or to
perform accurate and reliable spirometry.
Measures of inflammation, when they become available,
may also become useful. Other options for diagnosing
asthma are validated asthma questionnaires such as those
contained in the IPCRG guidelines,9 which help diagnostic
decision-making.
Diagnosing asthma in adults
Some of the symptoms of asthma are shared with diseases
of other systems. Thus, the differential diagnoses for adults
include respiratory and non-respiratory causes. Eliciting
a thorough medical history is essential. Patients may not
readily admit to smoking, occupational exposures, or
exposure to other triggers such as having pets. In addition,
comorbidities, such as gastro-oesophageal reflux disease,
allergic rhinitis, chronic obstructive pulmonary disease
(COPD), infection, cardiac disorders, and anaemia should
also be treated to successfully treat asthma.
Diagnosing asthma in children
The youngest patients, those under 5 or 6 years of age,
usually cannot perform the manoeuvres necessary for
accurate spirometry, and the diagnosis thus rests on
history, physical examination, and ancillary testing. In this
age group, differential diagnoses also include respiratory
(upper and lower) as well as non-respiratory causes.
Young children commonly wheeze with colds. A clinical
index of asthma risk aids in identifying children with
recurrent wheeze 2 years of age who are more likely to
develop persistent asthma: For children who have had four
or more wheezing episodes, the likelihood of asthma isgreater if they have one of three major risk factors
(parental history of asthma, personal history of physician-
diagnosed eczema, or allergic sensitization to 1 aero-
allergen) or two of three minor risk factors (allergic sensi-
tization to milk, egg, or peanuts, wheezing apart from
colds, and eosinophilia of 4%).10
It is useful to attempt to decide which phenotype of
childhood asthma is present to predict therapy needs and
duration.11,12 Transient childhood wheezers with no other
allergic diathesis often wheeze with respiratory viral infec-
tions because of their smaller airway calibre and the fact
that resistance to airflow increases with smaller calibre.
Reasons for poor asthma control: incorrect
choice of inhaler, poor technique
Poor inhaler technique is a common problem among
patients with asthma, and asthma control worsens as the
number of mistakes in technique increases (Fig. 1).13
Asthma guidelines stress the importance of patient training
in inhaler use.5,14 Moreover, trainers should be competent,
and inhaler technique should be rechecked at every routine
asthma consultation with patients demonstrating their
inhalation technique.
When inhaler devices areusedcorrectly, there is no clinical
difference between devices.15,16 However, each inhaler type
requires a different pattern of inhalation for optimal drug
delivery to the lungs. Each patient must be able to use their
device correctly to obtain optimal benefit. If possible, device
types should not be mixed for any individual patient.
The choice of inhaler for corticosteroid delivery is most
important because of the greater need to specifically and
accurately target the site of deposition. The choice of
inhaler for reliever bronchodilator therapy is less important
because of a wider therapeutic window; the patient can
compensate for poor technique by taking another inhala-
tion if the desired effect is not achieved.
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Currently available inhalers include (1) pressurised
metered-dose inhalers (MDIs), (2) breath-actuated MDIs
(BAIs), and (3) dry powder inhalers (DPIs).
Lung deposition of drug varies according to fine particle
dose (particles <5 mm) and characteristics of the particle
size range, as well as by inhaler device, ranging from as low
as 7% with beclometasone delivered by chlorofluorocarbon
(CFC)-propellant MDI to as high as 55% with extra-fine
beclometasone delivered by CFC-free hydroflouroalkane
(HFA)-propellant MDI. Lung deposition of beclometasone or
budesonide by DPI is intermediate (w33%).17 The use of
a spacer (with an MDI) approximately doubles lung
deposition.
Oropharyngeal deposition of an inhaled corticosteroid
(ICS) is important with respect to local side effects. Factors
that determine deposition in the mouth and throat are
particle size and the speed of inhalation, as well as the
velocity of the spray from an MDI. Inhaling from a spacer
device greatly reduces oropharyngeal deposition when
using a CFC-propellant MDI, whereas a spacer device may
not be as important for the new extra-fine CFC-free
beclometasone formulations, as the particles are smaller
and the force of the spray is less. A DPI has to be inhaled
with a fast inhalation hence there is a lot of oropharyngeal
impaction in the mouth and throat.
Metered-dose inhalers
MDIs are often used incorrectly13; therefore, it is important
that patients be trained to use them correctly. MDIs require
a slow and deep inhalation over 5 s with coordination
between dose release and the start of the inhalation.
However, only 8% of patients inhale slowly and deeply with
good coordination during routine use with their MDI.18 MDIs
can be used with spacers, large or small; however, a spacer
is the inhalation method least preferred by patients.19
The most common mistake patients make with these
devices is to inhale too fast.20,21 Other common problems
include poor coordination of actuation and inhalation
(solved by training or switching to a BAI); stopping after
inhalation when the cold spray hits the back of the throat
(‘‘cold Freon effect’’, solved by adding a spacer or
switching to CFC-free propellant); and inhaling through the
nose (solved through training).
If the patient uses a slow and deep inhalation, then good
coordination is not critical as long as the patient is inhaling
when they release the dose from an MDI.22 However,
despite training, patients will revert back to their bad
habits.23 It has been shown that lung deposition is less
affected by inhalation flow if the particles that are emitted
from an inhaler are ultrafine.24 Some of the reformulated
CFC-free propellant corticosteroid MDIs deliver ultrafine
particles and thus help overcome the problem of inhalation
speed. Moreover, use of a BAI, easier to use than a tradi-
tional MDI, can translate to improved outcome in terms of
better asthma control.25
Dry powder inhalers
DPIs require a rapid acceleration rate during the initial part
of the inhalation manoeuvre to transform the metered dose
into a quality dose that has the greatest potential for lungdeposition. In the past the emphasis has been on the peak
inhalation rate, but if this is reached slowly by the patient,
then the initial acceleration rate may be insufficient to
produce the required quality dose. Failure to inhale deeply
and forcibly at the start of the inhalation manoeuvre means
that the drug particles generated are too big to enter the
lungs and are simply deposited in the mouth and
oropharynx where they have no clinical efficacy. Moreover,
if the patient does not inhale fast enough or long enough,
not all the dose is emitted.26
Young children have trouble achieving the minimum rate
of inspiratory flow and thus DPIs should not be prescribed to
children <5 years old.27 Sensitive to moisture, DPIs should
be stored in a dry place, and patients should take care not
to blow into the inhaler, as this will affect dose delivery.
Devices to aid inhaler technique
Schematic cartoons illustrating inhaler technique for
several devices are available on the Asthma UK website28;
and inhaler and spacer diagrams are available on the GINA
website.29 In addition, relatively inexpensive devices to
check technique and maintain trained technique are now
available, and more are being developed, such as the
Aerosol Inhalation Monitor (AIM, Vitalograph Ltd, Bucking-
ham, England); the 2Tone Trainer (Canday Medical Ltd.,
Newmarket, England); the AeroChamber Plus spacer
(Forest Pharmaceuticals, Inc., St. Louis, US); and the In-
Check Dial (Clement Clarke International Ltd., Essex, UK).
The Turbuhaler whistle (AstraZeneca International, Lon-
don, UK) is an example of a simple device that has been
introduced to check for the required inhalation rate for
patients prescribed this device. The Novolizer (MEDA
Pharma GmbH & Co. KG, Bad Homburg, Germany) has been
designed to release its dose only when the required inha-
lation rate is achieved.
Beyond device choicedimproving inhaler
technique
When choosing an inhaler device, it is important to take
account of patients’ preferences and views, as well as to
simplify the regimen and not mix inhaler types. Patients
should be trained to use their inhaler devices properly, and
their technique should be rechecked on each revisit.
Observation of technique by a health professional or by
patients themselves, perhaps on video in some settings, can
be useful to detect problems. Use of more tolerant devices,
such as BAIs, can be helpful for some patients. Finally, oral
controller therapy (antileukotriene) is a consideration for
patients with mild to moderate asthma who continue to
have difficulty with their inhaler. Licensing approval for this
option varies in different countries and for different age
groups.
Reasons for poor asthma control: smoking
There is clear evidence now that concurrent smoking
adversely impacts asthma control. The prevalence of current
smoking among patients with asthma varies by country from
15% to 25%.30,31 In a retrospective cohort study of a large UK
Figure 2 Effect of inhaled corticosteroid (ICS) therapy versus placebo (PL) on lung function among patients with chronic asthma.
Baseline FEV1 improved significantly in the ICS-treated arm compared with placebo. However, when dividing the patients according
to smoking habit (SZ current smoker, NSZ nonsmoker), the effect on lung function was seen only among the non-smoking
patients. Adapted with permission from Kerstjens et al.33
Figure 3 Mean (95% CI) peak expiratory flow (L/min) in non-
smoking and smoking patients with asthma after treatment
with inhaled placebo or fluticasone propionate 1000 mg/day.
)pZ 0.016, greater than non-smokers after placebo;
))pZ 0.001, greater than smokers after fluticasone. From
Chalmers et al.34 Reproduced with permission from the BMJ
Publishing Group.
Understanding poor asthma control 1685general practice database, current smokers were almost 3
times more likely than non-smokers to be hospitalised for
their asthma over a 12-month period.32
Suboptimally controlled asthma in smokers may be the
result of concomitant COPD or asthma misdiagnosed as
COPD. An alternative explanation is that ICS therapy fails
more often in smokers. Studies of smokers with asthma
indicate that these patients respond differently to corti-
costeroids than do non-smokers.
In one Dutch study, the effect of ICS was compared with
placebo, using lung function and airway hyper-
responsiveness as primary outcome variables.33 A highly
significant improvement in FEV1 was found in the arm
treated with ICS compared with placebo. However, when
the patients were segmented according to smoking status,
benefits were noted only in the non-smoking group (Fig. 2).
A study published in 2002 further illustrates the lack of
effects of ICS for treating patients with asthma who smoke:
in this study of patients with mild asthma, fluticasone had
no effect on lung function or sputum eosinophils in smokers
(Fig. 3).34
Eosinophil and neutrophil activity in smokers is not
reduced by ICS therapy, even at high doses.35 Moreover, the
correlation between exhaled nitric oxide, a marker of
eosinophilic airway inflammation, and airway hyper-
responsiveness is lost in smokers.36 Administration of high-
dose ICS therapy did not improve lung function among
smokers with asthma in one study,35 and results were not
definitive in a second study.37
Reasons for relative corticosteroid resistance
among smokers with asthma
There are three reasons currently proposed for the relative
corticosteroid resistance among smokers with asthma.
Firstly, the pattern of airway inflammation in smokers is
different from that in non-smokers with asthma: smokers
have a higher percentage of neutrophils in induced
sputum,38 and corticosteroids are not very effective in
reducing neutrophils. Among patients who stop smoking,
there is a large reduction in sputum neutrophil count.39
Thus, neutrophilic inflammation responds to smoking
cessation but not to corticosteroids.Secondly, smoking produces oxidative stress, which
impairs the activity of histone deacetylase-2 (HDAC2),40
resulting in reduced anti-inflammatory activity of cortico-
steroids. Finally, smoking triggers leukotriene production in
patients with asthma, and leukotrienes are not reduced by
corticosteroid therapy.41
Clinical approach to patients with asthma
suspected or known to smoke
These findings highlight the importance of identifying
current smoking habits of patients with asthma, particu-
larly those whose symptoms are poorly controlled. While an
oral history may not elicit this fact, patients may admit to
smoking when asked via a written self-completed ques-
tionnaire, as they may feel less threatened. For patients
who are suspected or confirmed smokers, the consultation
should include investigations to exclude COPD.
The ideal therapy for patients with asthma who smoke is
smoking cessation.42 In the absence of that, therapeutic
1686 J. Haughney et al.alternatives to low-dose ICS are a leukotriene receptor
antagonist (LTRA), theophylline, or possibly high-dose ICS
(up to 1600 mg/day).
The LTRA montelukast seems to have some effect in
smokers with asthma, as shown by a recently performed
pilot study.43 These results need to be confirmed in larger
clinical trials. From a theoretical point of view, combina-
tion therapy with ICS and long-acting b2-agonist or
theophylline could have a beneficial effect in smokers.
While long-acting b2-agonist was found to suppress
tobacco-induced macrophage activation44 and improve
airway mucociliary clearance,45 theophylline to some
degree prevents suppression of the histone deacetylase
inflammatory gene believed to be important in smoke-
induced corticosteroid resistance.46 However, convincing
clinical data are lacking and thus we do not yet have any
solid recommendations for how to treat this large group of
patients.
Reasons for poor asthma control: co-morbid
rhinitis
Asthma and rhinitis, both allergic and nonallergic, are
linked in many ways: they share a similar epidemiology
(most patients with asthma have rhinitis), and they have
common triggers.47e49 The pattern of inflammation is
similar, involving T helper type 2 cells, mast cells, and
eosinophils. Moreover, nasal challenge results in asthmatic
inflammation and vice versa.50,51 Finally, the presence of
rhinitis predicts the development of asthma.49
Asthma patients with rhinitis use more health-care
resources than those without rhinitis, indicating that their
asthma is less well-controlled. In a retrospective cohort
study of 27,000 adult patients with asthma included in
a large UK general practice database, patients with
concomitant rhinitis were 50% more likely to be hospitalised
for their asthma, and significantly more likely to visit their
primary care physician, over a 12-month period than those
without rhinitis.32 Moreover, the presence of concomitant
rhinitis was associated with significantly higher drug use
and costs among these patients with asthma. For children in
a similar study, the presence of concomitant asthma and
rhinitis more than doubled the likelihood of being hospi-
talised and significantly increased the likelihood of
a physician visit for asthma.52 All levels of rhinitis can
impact on asthma control: the percentage of adult patients
with poor asthma control is greater even among those with
mild rhinitis, as compared with patients with asthma alone.
Clinical approach to patients with asthma
and concomitant rhinitis
The question thus arises whether treatment for rhinitis will
improve asthma control. While this question requires
further study, preliminary data would suggest that it does.
In a trial of patients with chronic moderate asthma
comparing the effect of doubling budesonide versus adding
montelukast, no difference was found between the two
arms, using lung function and symptom control as primary
parameters. However, patients with co-morbid rhinitis who
received budesonide plus montelukast showed significantlygreater improvement in morning PEF and other clinical
outcomes than the group receiving monotherapy with
doubled dose of budesonide, suggesting that the effects of
a regime treating both the upper and lower airways
improved lower airway function most (Fig. 4).53 The
difference became even more pronounced in the limited
number of patients needing treatment for their rhinitis (see
Fig. 4).
While a good history and examination of the nose will aid
in the diagnosis of rhinitis, the patient’s answer to a single,
practical question, adapted from that used by the Inter-
national Study of Asthma and Allergies in Childhood
(ISAAC),54 may be all that is needed to diagnose rhinitis:
‘‘Do you have an itchy, sneezy, runny, or blocked nose
when you don’t have a cold?’’
The inflammation of both upper and lower airways
should be treated to obtain optimal clinical outcomes
(Table 1).55,56 Nasal corticosteroids may possibly improve
asthma control when used in conjunction with ICS, although
the evidence supporting this is limited at this point.
Reasons for poor asthma control: individual
variation in response to treatment
Limitations of randomised controlled trials
Traditional, formal randomised controlled trials (RCTs) are
established as the bed-rock of recommendations made by
clinical guidelines. The current focus of clinical trials in
asthma is driven by many factors, including regulatory
requirements, history (what’s been done in the past and is
therefore still expected), ease of measuring certain
endpoints, available technology to measure these
endpoints, the needs of industry, the need to focus on
short-term events of asthma (from where the most obvious
costs stem, such as from hospitalisation), and the limited
number of agents available for treating asthma. The design
of RCTs, quite properly, usually involves attempts to
remove all possible confounding factors to allow assess-
ment of the intervention studied. This can, however, lead
to difficulties with translation of the results of the study,
either directly or through a guideline recommendation, due
to an inability to generalise the study to a true clinical
population.
The conduct of a study, often involving increased
contact with health-care professionals and higher levels of
education and training, may influence compliance with
therapy, competence in administration, and adherence to
more complex therapeutic regimes (perhaps involving
multiple, perhaps dummy, therapies) than is seen in stan-
dard clinical practice. Adherence is believed to be consid-
erably better in clinical trials than in real life and this can
of course be important when a tablet is compared with an
inhaled drug. In real life, adherence to ICS is usually
between 30% and 40%.57
Regulatory authorities’ decision to place a very high
emphasis on lung function, particularly FEV1, as both an
entry criterion and as the primary outcome of clinical
trials can both influence patient selection and also detract
from other, perhaps more patient-focused, outcomes.
Figure 4 Change from baseline in morning peak expiratory
flow for patients who received montelukast 10 mg once dai-
lyþ budesonide 400 mg twice daily or budesonide 800 mg twice
daily. (A) All patients, (B) patients with asthma and concomi-
tant allergic rhinitis, (C) patients with concomitant rhinitis
requiring regular treatment. From Price et al.53 Adapted with
permission from Wiley-Blackwell.
Table 1 Treatment of comorbid rhinitis and asthma
Upper airway
treatment options
Lower airway
treatment options
Nasal corticosteroids Inhaled corticosteroids
Antihistamines
Upper and lower airway treatment options
1. Leukotriene receptor antagonists
2. Anti-IgE
3. Immunotherapy
Understanding poor asthma control 1687Indeed, the recommendations from the European Medi-
cines Agency (EMEA) call for evidence of >15% reversibility
in FEV1 after short-acting bronchodilator for patients
enrolled in clinical trials. This criterion alone excludes
many patients with asthma from clinical trials (not all
patients with asthma show substantial reversibility at one
point in time), and, furthermore, selects those patients
more likely to be responsive to b2-agonist. Careful selec-
tion of participants in a clinical trial can clearly influence
the study’s results.58
Clinical study patients versus real-life patients
An important question thus is whether the patient
selected for a clinical trial is representative of the larger
number of patients treated for asthma by physicians,
namely, real-life asthma patients. The answer to this
question is obviously ‘‘no,’’ as most patients with any co-
morbid condition are excluded from most randomised
clinical asthma trials. In fact, two studies suggest that only
a small percentage of people with asthma in a general
practice population would satisfy all the entry criteria and
none of the exclusion criteria for typical formal RCTs in
asthma.59,60
It is a discredit to the respiratory research community
that so few studies have focused on, or even included, the
considerable percentage of people with asthma who
smoke, and the few studies that include ‘‘smoking asth-
matics’’ convincingly show that ICS treatment has marginal
effects for them compared with those who do not smoke, as
discussed above. Similarly, from clinical epidemiologic
studies we know that the majority of patients with asthma
have concomitant rhinitis and that the rhinitis component
affects patients’ well-being as well as interferes with
treatment effect.61
Another important factor is patient perception of their
disease, as many patients fail to perceive their level of
asthma control. This factor is not unimportant when
a symptom-based approach is being used to achieve optimal
disease control.62,63 The lack of perception does not seem
to be related to degree of disease knowledge or any obvious
personal characteristics.64 Moreover, low perception is
commonly found in patients with more severe disease,65
with increased hyperresponsiveness and lower lung func-
tion.66 As perception and a documented need to take extra
rescue medication are common inclusion criteria in clinical
trials, it is reasonable to assume that patients with low
perception are being excluded.
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Data from clinical trials are usually reported as group mean
data. This helps us to know how best to treat a population
but may not help us in the real-life clinical scenario: one
patient in the clinician’s office. Results of two studies
comparing an ICS versus an LTRA as anti-inflammatory
strategies indicate that mean data do not always apply to
the individual patient.
In the study by Malmstrom et al.,67 beclometasone was
compared with montelukast for patients with chronic
asthma. In the beclometasone group there was a mean
improvement in morning PEF of 39 L/min, significantly
better (p< 0.001) by an additional 64% than for mon-
telukast (24 L/min). A completely different picture is seen,
however, at an individual level analysis. An increase in FEV1
of 11%, a clinically relevant improvement, was seen for
42% of montelukast-treated patients and 50% of the
beclometasone-treated patients (Fig. 5). Moreover, the
number of severe asthma exacerbations was the same for
both groups.
The obvious follow-up questions to the results will be a)
were the patients selected for the study representative of
a larger patient population? and b) were the patients who
responded positively to montelukast also by nature
responders to beclometasone? Regarding patient selection,
all patients had chronic persistent asthma with at least 15%
confirmed reversibility to short-acting b2-agonist; about
65% had concomitant rhinitis. Unfortunately, no data were
reported on response pattern in various clinical
phenotypes.
Whether montelukast-responsive patients also respond
to ICS was investigated in a second study comparing mon-
telukast with fluticasone propionate for young patients
with mild persistent asthma.68 Fluticasone treatment was
superior to montelukast treatment with regard to number
of asthma control days, with a mean of 5 versus 4.3 asthma
control days for montelukast (p< 0.001). However, if one
examines individual response data, both treatmentFigure 5 Distribution of clinical response measured as
change from baseline FEV1 after treatment with beclometa-
sone 200 mg twice daily (white bars) or montelukast 10 mg once
daily (striped bars). Reprinted with permission from Malmstrom
et al.67alternatives provided equal clinical effect in the majority
of patients (60%). Moreover, in a limited number of patients
(nZ 15, or 12%), montelukast provided a better clinical
effect than fluticasone (Fig. 6).
These findings clearly illustrate the need to carefully
monitor treatment effect for each individual patient.
A highly significant difference in the mean increases the
likelihood of one drug being more effective than the other.
However, to forecast the effect in a single patient requires
more specific phenotypic information. For example, in the
latter study,68 a high level of exhaled nitric oxide and
frequent use of rescue ß2-agonist increased the likelihood
of getting a better response from fluticasone treatment.
However, for most of the patients no clear relation
between clinical phenotype and drug response was seen.
The presence of atopy and current smoking status are
obvious examples of phenotypes easily identified in the
clinical setting (although not all patients will admit to
smoking!). However, even in these groups, response to
treatment can vary considerably. For understandable
reasons, the pharmaceutical industry has traditionally been
reluctant to define subgroups of good responders, and
randomised trials including a large number of carefully
selected patients have been the gold standard for many
years. Highly significant statistical differences between
treatment modalities are easy to reach when large numbers
of patients are included. However, statistical difference
does not always imply clinically relevant difference. From
the attending doctor’s perspective it is more important to
identify clinically relevant changes for the individual
patient.Figure 6 Response to treatment with montelukast 5e10 mg
once daily compared with fluticasone propionate 100 mg twice
daily in children aged 6e17 years with mild to moderate
asthma. An asthma control day was briefly defined as no day-
or night-time symptoms, no use of rescue medication, PEF
>80% of baseline, and no social or functional limitations
secondary to asthma. Each line designates a single participant.
Reprinted with permission from Zeiger et al.68
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Pharmacogenetic analyses may help in the future to iden-
tify potential responders. Beta-2 receptor polymorphism is
one example for which studies have indicated that patients
homozygous for arginine (arg/arg) at amino acid 16 on the
b-receptor gene are less responsive to b2-agonist and more
prone to develop tolerance to regular treatment.69,70 This
has, however, been questioned in a recent study by
Bleecker et al.,71 who could not find obvious differences
between the genotypes. Other studies have found genetic
variability in the 5-lipoxygenase gene identifying subtypes
less prone to respond to 5-LO inhibitors72 and genetic
polymorphism on the LTC4-synthase gene possibly identi-
fying different responders to LTRA treatment.73 However,
the results produced so far are not definitive, and the field
of pharmacogenetics needs to be further developed before
findings can be used with confidence in clinical practice.
Reasons for poor asthma control: patients’
beliefs and adherence
Prescribed treatments are effective only if taken. Patient
nonadherence to treatment is an important problem across
chronic illnesses, with as much as 30e50% of prescribed
medications not taken as directed.74,75 This level of non-
adherence represents a loss to health-care systems,
because of wasted resources and costs of inadequate
treatment, and to patients, because of the missed oppor-
tunity for improving health.76
In asthma, nonadherence to controller therapy, espe-
cially ICS, is common and is likely a factor in poor asthma
control.77,78 However, nonadherence is often a hidden
problem because it is not commonly assessed at routine
asthma visits. Patients may be reluctant to admit non-
adherence to avoid disappointing their physician, and
physicians may be reluctant to query about adherence
because they lack a clear and easy method to improve it.
Formal interventions to improve adherence have not been
successful,79 perhaps because of lack of complete under-
standing about the causes of nonadherence.
The perceptual-practical model of nonadherence
Causes of nonadherence can be broken down into two
categories: unintentional and intentional non-
adherence.76,80 Unintentional nonadherence results from
practical barriers to treatment, such as language barriers,
forgetfulness, and inadequate understanding of the
instructions. Poor inhaler technique falls under this cate-
gory. Intentional nonadherence results from patient choice
to take less medication than prescribed (or none), or to
take it differently than prescribed.
The term concordance describes the degree to which the
patient and health-care provider agree about the nature of
the patient’s illness and chosen treatment path.76,81 As
such, concordance (1) recognises that patients and health-
care providers bring to the consultation two sets of
(potentially opposing) beliefs about the illness and treat-
ment, and (2) incorporates a presumption of adequate
communication between patient and health-care provider.When beliefs differ, and the patient and provider fail to
reach an understanding during the consultation, no
concordance is the result, and patient nonadherence to
treatment is more likely.
Assessing necessity beliefs and concerns: the necessity-
concerns framework
Intentional nonadherence is often related to patients’
personal beliefs about treatment, particularly the way in
which they judge their personal need for treatment relative
to their concerns about potential adverse effects, with low
adherence associated with doubts about necessity and with
concerns. This framework seems to explain nonadherence
across many chronic illnesses. Both factors are relevant in
most situations, and there may be an interplay between
them: for example, in a situation of low necessity, concerns
may become more salient. Types of concerns and, more
commonly, levels of concerns vary from individual to indi-
vidual, and there may also be cultural differences.82
In asthma, patients often doubt the necessity of taking
a daily medication for a condition that they experience
episodically. For example, in the worldwide AIRE survey,
people commonly underestimated the seriousness of their
symptoms (and overestimated control of their asthma).1
Moreover, patients often have concerns about potential
side effects from taking ICS. In a recent study, patients’
beliefs about ICS were shown to correlate with their
adherence, as measured both by self-report as well as by
pharmacy prescribing records.83
Tools to assess patients’ beliefs and identify
adherence behaviour
Interventions to facilitate optimal adherence are likely to
be more effective if they identify adherence behaviour,
identify the mix of perceptual and practical barriers for the
individual, and tailor the intervention and support accord-
ing to specific barriers and patient preferences. Non-
adherence is relevant, of course, only if asthma symptoms
are poorly controlled.
The Beliefs about Medicines Questionnaire (BMQ) was
developed to measure necessity beliefs and concerns and
has been validated for use in a range of chronic illnesses,
including asthma.84 An-11 item asthma-specific version can
be used to identify patients’ doubts about the necessity of
taking controller medication and concerns about potential
adverse effects. Patients are asked if they agree or
disagree, on a 5-point scale, with the statements.
The Medication Adherence Report Scale (MARS) was
developed to assess patient adherence, with the goal of
facilitating honest self-report.85 The MARS for measuring
adherence to ICS therapy consists of five statements
described as being ‘‘ways in which people have said that
they use their preventer inhaler.’’ The patient is asked
whether their way of using their own preventer inhaler
applies to the statements.
The Minimal Asthma Assessment Tool (MAAT) is being
pilot-tested in the UK as a paper or online questionnaire.
This simple, self-administered patient questionnaire
incorporates the short clinical version of the BMQ and MARS
in addition to questions assessing asthma control, the
presence of smoking or rhinitis, any practical difficulties
1690 J. Haughney et al.with treatment, as well as the extent of a patient’s doubts
about the necessity of taking controller medication for
asthma and concerns about associated side effects.86Reasons for poor asthma controldsummary
and next steps
Reviewing the diagnosis of asthma is the first step in
assessing poor symptom control. Differential diagnoses vary
by age, and tools developed to aid asthma diagnosis need to
reflect this. A simple question can identify patients with
concomitant rhinitis, a common reason for sub-optimal
asthma control. Smoking is another factor that is now
a well-established cause of poor asthma control. Patients
may be more likely to admit to current smoking on a written
questionnaire than during a face-to-face consultation.
Preliminary results from the MAAT87 suggest that this
simple, easy-to-complete tool might assist asthma review in
primary care. Eliciting patients’ views about therapy could
help guide discussion to address perceptual barriers to
taking maintenance therapy (doubts about personal
necessity and concerns about potential adverse effects)
and practical barriers such as poor inhaler technique. Tools
such as the MAAT that are completed by the patient before
the consultation, that reflect the patient’s perspective
back to the clinician, can save valuable clinic time, because
the findings can serve as a starting point for discussion and
problem solving during the consultation, rather than the
consultation period being spent in identifying problems.
Strategies to develop open, communicative, non-judge-
mental relationships with patients and to let patients take
an active part in the planning process have been stressed.88
In this way the caregiver can adopt a partnership approach
to asthma management. There is increasing evidence that
patient-focused strategies, including shared decision-
making and individualised verbal and written information,
can improve the patient’s experience.89
One area that remains challenging is poor inhaler tech-
nique. The development of videos demonstrating proper
technique and care for each inhaler type could be useful in
this regard albeit there are practical hurdles to overcome.
All tools for aiding asthma diagnosis and management in
primary care will require translation into local languages as
well as adaptation to address cultural differences in
perceptions about asthma, in particular the stigma associ-
ated with an asthma diagnosis that is present to varying
degrees in many countries. Moreover, tools will require
rigorous testing to address issues of low levels of health
literacy in many countries.89
To support these efforts, further study is needed
regarding the factors and patient characteristics that could
predict individual responses to asthma therapies, and it is
important that future research address this vital issue.
Identifying these factors will require studies to map
response distributions to different therapies according to
patient characteristics and comorbidities. In addition,
information is needed from clinical trials that enrol patient
populations reflecting the real world diversity of patients
seen in primary care, including wide age ranges, presence
of comorbidities, current smoking, differing ethnic origins,
and cultural diversity. Specific asthma phenotypes may bedifficult to study but nonetheless require study to identify
optimal treatment. Ultimately, we hope this information
can be incorporated into tools to help clinicians to optimise
asthma therapy and to greater enable each patient to have
full quality of life with minimal or no impediment from
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